Welcome to our dedicated page for Vigil Neuroscience news (Ticker: VIGL), a resource for investors and traders seeking the latest updates and insights on Vigil Neuroscience stock.
Vigil Neuroscience, Inc. (formerly Nasdaq: VIGL) generated news as a clinical-stage biotechnology company focused on microglia and TREM2-targeted therapies for neurodegenerative diseases. Company announcements highlighted progress across its two main programs: iluzanebart, a fully human monoclonal antibody TREM2 agonist for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), and VG-3927, a novel orally bioavailable small molecule TREM2 agonist for common neurodegenerative diseases, initially Alzheimer’s disease.
News coverage for Vigil included clinical trial updates, such as data from the Phase 2 IGNITE trial of iluzanebart in ALSP and Phase 1 trial results for VG-3927, which assessed safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers, elderly participants, and Alzheimer’s disease patients. The company also reported on its ILLUMINATE natural history study in ALSP, which was designed to improve understanding of disease progression and biomarkers.
Corporate and strategic developments were another major source of news. Vigil disclosed a strategic investment from Sanofi tied to its small molecule TREM2 agonist program and later announced a definitive merger agreement under which Sanofi would acquire Vigil. Subsequent news detailed shareholder approval, litigation-related disclosure supplements, and the completion of the acquisition, after which Vigil became a wholly owned subsidiary of Sanofi.
This news archive allows readers to follow Vigil Neuroscience’s historical clinical milestones, scientific presentations at neurology-focused conferences, financing and strategic transactions, and the regulatory steps that led to its delisting and deregistration as an independent public company.
Vigil Neuroscience (NASDAQ: VIGL) presented data on VG-3927, its oral small molecule TREM2 agonist, at the AD/PD™ 2025 International Conference. The company shared results from both preclinical studies and Phase 1 SAD/MAD trial for potential Alzheimer's disease treatment.
Key findings from the Phase 1 trial involving 115 participants showed:
- Favorable safety and tolerability profile with no serious adverse events
- High CNS penetrance with CSF to unbound plasma ratio of 0.91
- Maximum sTREM2 reduction of approximately 50% at 25mg dose
- Support for once-daily dosing at 25mg for Phase 2 trial
Preclinical data demonstrated VG-3927's ability to enhance microglial uptake of both Aβ and Tau in 5xFAD plaque-burdened mice, suggesting potential broader efficacy in targeting multiple AD pathologies. The company plans to advance to Phase 2 development in Q3 2025.
Vigil Neuroscience (VIGL) reported its Q4 and full year 2024 financial results, highlighting significant progress in its TREM2 programs. The company announced positive Phase 1 data for VG-3927, their oral small molecule TREM2 agonist for Alzheimer's Disease, demonstrating favorable safety and up to 50% reduction in sTREM2 in cerebral spinal fluid. A Phase 2 trial is planned for Q3 2025.
The company's financial position shows cash reserves of $97.8 million as of December 31, 2024, expected to fund operations into 2026. R&D expenses increased to $62.3 million for 2024 (from $60.9M in 2023), while G&A expenses decreased to $27.4 million (from $27.9M). Net loss for 2024 was $84.3 million.
The company expects to report final analysis from the IGNITE Phase 2 trial of iluzanebart for ALSP in Q2 2025, pursuing an accelerated approval pathway.
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotechnology company focused on microglia-based treatments for neurodegenerative diseases, has announced its upcoming participation in the Stifel 2025 Virtual CNS Forum.
The company's management will engage in a fireside chat scheduled for Wednesday, March 19, 2025, at 9:00 a.m. ET. The presentation will be accessible through a live webcast, with registration available online. Additionally, the webcast will be hosted in the 'Investors' section under 'Events & Presentations' on the company's website, remaining available for approximately 90 days after the event.
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotechnology company focused on microglia-based treatments for neurodegenerative diseases, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference. The company's management will engage in a fireside chat on February 6, 2025, at 10:30 a.m. ET.
The event will be accessible through a live webcast, for which registration is required. The presentation will also be available on the company's website in the Investors section under Events & Presentations, with the archived version remaining accessible for approximately 90 days after the event.
Vigil Neuroscience (VIGL) announced positive data from its completed Phase 1 clinical trial of VG-3927, an oral treatment for Alzheimer's disease (AD). The trial, involving 115 participants across 14 cohorts, demonstrated favorable safety and tolerability profiles with no serious adverse events.
Key findings include: highly brain penetrant properties, dose-dependent reduction of sTREM2 up to 50% in cerebral spinal fluid, and consistent pharmacokinetics across different genetic variants. The company selected a 25mg once-daily oral dose for its planned Phase 2 trial, scheduled to begin in Q3 2025.
VG-3927, as the first Phase 2-ready oral TREM2 agonist, functions as both an agonist and positive allosteric modulator. The drug is designed to enhance protective microglial responses to aggregated amyloid and tau without increasing inflammation, potentially offering advantages over antibody-based treatments by avoiding ARIA risks.
Vigil Neuroscience (NASDAQ: VIGL) highlighted its 2024 achievements and 2025 milestones. The company reported significant progress in its two TREM2 agonist programs and secured a $40 million strategic investment from Sanofi. Key developments include completing enrollment of 20 patients for the IGNITE Phase 2 trial of iluzanebart and surpassing 50 participants in the ILLUMINATE natural history study for ALSP.
The FDA indicated openness to considering accelerated approval for iluzanebart in ALSP. The company's VG-3927 program showed positive interim Phase 1 data in healthy volunteers and initiated dosing in Alzheimer's disease patients. The FDA removed a partial clinical hold on the VG-3927 trial.
Looking ahead to 2025, Vigil plans to report Phase 1 data for VG-3927 in Q1 and final analysis from the IGNITE Phase 2 trial for iluzanebart in Q2.
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotech company focusing on microglia-based treatments for neurodegenerative diseases, has announced its participation in two major investor conferences. The company will present at the Stifel 2024 Healthcare Conference on November 18th at 4:45 p.m. ET and the Jefferies London Healthcare Conference on November 20th at 8:30 a.m. GMT. Both presentations will be in a fireside chat format. The webcasts will be accessible through the company's website's Investors section and will remain available for approximately 90 days after the presentations.
FAQ
What is the current stock price of Vigil Neuroscience (VIGL)?
What is the market cap of Vigil Neuroscience (VIGL)?
